Health
LoDoCo2: Added Steam for Colchicine as Secondary Prevention – Medscape
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard prevention therapies in the double-blind LoDoCo2 study.
Across a median follow up of 29 months in more than 5000 patients, almost 1 in 10 patients assigned to placebo experienced the primary endpoint of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revas…
-
Noosa News18 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News22 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General18 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News17 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland